Fludarabine
Myeloid Malignancies
First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
29 Active assets in the Myeloid Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mitoxantrone First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cladribine University of Washington | Phase 2 | BBB |
Cyclophosphamide Prelude Therapeutics | Phase 3 | BB |
Idarubicine Northwestern University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →